BioCryst Pharmaceuticals BCRX Total costs & expenses
Total costs & expenses at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CostsAndExpenses.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's total costs & expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's total costs & expenses?
- BioCryst Pharmaceuticals (BCRX) reported total costs & expenses of $858.01M in Q1 2026.
- How has BioCryst Pharmaceuticals's total costs & expenses changed year-over-year?
- BioCryst Pharmaceuticals's total costs & expenses increased by 590.2% year-over-year, from $124.31M to $858.01M.
- What is the long-term trend for BioCryst Pharmaceuticals's total costs & expenses?
- Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's total costs & expenses has grown at a 12.4% compound annual growth rate (CAGR), from $334.89M to $533.85M.
- What does total costs & expenses mean?
- The aggregate of all operating and non-operating costs incurred by the company during a reporting period, including research and development, selling, general, and administrative expenses. This metric provides a comprehensive view of the total resource consumption required to sustain business operations and drug development pipelines.